17 November 2026 | Tuesday | News
Image Source: Public Domain
Designation covers daretabart in combination with induction chemotherapy for first-line treatment in paediatric patients
First Breakthrough Therapy Designation (BTD) for daretabart, an investigational anti-GD2 humanised monoclonal antibody
Daretabart is an investigational asset and has not been approved for use by any regulatory authority
Renaissance Pharma Limited (Renaissance Pharma), an Essential Pharma company focused on development stage assets, announces that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for use of daretabart (hu14.18K322A) in combination with induction chemotherapy, for the first-line treatment of paediatric patients with newly diagnosed high-risk neuroblastoma (HRNB).
This designation was supported by Phase II data published in the Journal of Clinical Oncology in December 20211. The study was an open label, single arm Phase II trial at one centre in 64 children with newly diagnosed HRNB. Three-year event-free survival (EFS) was 73.7% (95% CI 60.0 to 83.4) and three-year overall survival (OS) was 86.0% (95% CI 73.8 to 92.8). Grade 3 or 4 toxicities attributed to the antibody infusion during induction included pain (10% of 379 cycles), hypoxia (6%), infusion related reactions (4%), hypotension (3%) and cough (1%).
The FDA's BTD program is intended to expedite the development and review of investigational medicines with clinical evidence that may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.
Simon Ball, President of Renaissance Pharma said, “We look forward to executing our clinical development strategy, including our ongoing SHINE study in relapsed and refractory disease, together with our future planned induction study, to bring this antibody to the neuroblastoma community.”
© 2026 Biopharma Boardroom. All Rights Reserved.